Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic acid bile pharmacokinetics/pharmacodynamics in PBC, NASH, and healthy controls
2016-002965-67Phase 2Active
- Sponsor
- AMC Health
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of obeticholic acid in primary biliary cholangitis (PBC) and metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by AMC Health. Primary endpoint: Bile acid concentrations in plasma and bile. Started Mar 2017; status: active.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2016-002965-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002965-67.